Skip to main content
. 2013 Oct 10;6:1425–1435. doi: 10.2147/OTT.S34678

Table 1.

A list of hedgehog signaling inhibitors in clinical trials (from http://clinicaltrials.gov)a

Molecule Other names Phase Tumor types FDA approval Company
GDC-0449 Vismodegib/erivedge I/II/III BCCs and solid tumors BCCs Hoffmann-La Roche Ltd
IPI-926 I/II Solid tumors Infinity Pharmaceuticals, Inc.
LDE225 I/II Leukemia and solid tumors Novartis AG
LEQ506 I Solid tumors Novartis AG
PF-04449913 I/II Leukemia and solid tumors Pfizer, Inc.
TAK-441 I Solid tumors Millennium Pharmaceuticals, Inc.
BMS833923 XL-139 I/II SCLC and solid tumors Bristol-Myers Squibb
LY2940680 I/II SCLC/advanced cancer Eli Lilly and Company

Notes:

a

All small molecules target smoothened molecule. GDC-0449 has been approved by the FDA to treat locally advanced and metastatic BCCs. There are no ongoing clinical trials for LEQ506, TAK-441, and BMS833923.

Abbreviations: BCC, basal cell carcinoma; FDA, US Food and Drug Administration; SCLC, small cell lung cancer.